Compare Abbott Laboratories (ABT) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Freshworks Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Freshworks Inc trades at $10.26 (market cap $2.87B). The key difference: Abbott Laboratories is far larger — about 58.2× Freshworks Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| ABT | FRSH | |
|---|---|---|
Market Cap | $166.94B | $2.87B |
Sector | Health | Technology |
52-Week High | $136.62 | $15.36 |
52-Week Low | $82.57 | $6.88 |
Enterprise Value | $193.69B | $2.13B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Freshworks (FRSH) trades at $10.38, up 0.39% with a bullish technical signal. The company shows strong revenue growth from $498M in 2022 to $839M in 2025, achieving profitability with a net margin of 20.69%. Recent news highlights AI-driven service platform adoption, including Vanquis selecting Freshservice. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook is positive due to accelerating revenue growth and expanding margins, though high EV/EBITDA of 48.15 suggests premium valuation. Risks include competitive pressures in SaaS and execution challenges in sustaining growth. Upside potential exists if the company maintains its earnings beat trend and capitalizes on AI integration demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
